 Oligopeptides
"Oligopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides composed of between two and twelve amino acids.
| Descriptor ID |
D009842
|
| MeSH Number(s) |
D12.644.456
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligopeptides".
Below are MeSH descriptors whose meaning is more specific than "Oligopeptides".
This graph shows the total number of publications written about "Oligopeptides" by people in this website by year, and whether "Oligopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 2 | 3 | 5 | | 1985 | 1 | 1 | 2 | | 1986 | 1 | 1 | 2 | | 1987 | 1 | 0 | 1 | | 1989 | 0 | 1 | 1 | | 1990 | 2 | 1 | 3 | | 1991 | 2 | 0 | 2 | | 1992 | 3 | 0 | 3 | | 1993 | 0 | 3 | 3 | | 1994 | 1 | 2 | 3 | | 1995 | 4 | 0 | 4 | | 1996 | 3 | 1 | 4 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 3 | 4 | | 1999 | 3 | 2 | 5 | | 2000 | 0 | 4 | 4 | | 2001 | 2 | 2 | 4 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 4 | 5 | | 2005 | 4 | 1 | 5 | | 2006 | 1 | 1 | 2 | | 2007 | 5 | 1 | 6 | | 2008 | 1 | 2 | 3 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 3 | 5 | | 2011 | 5 | 2 | 7 | | 2012 | 5 | 7 | 12 | | 2013 | 3 | 5 | 8 | | 2014 | 7 | 2 | 9 | | 2015 | 2 | 1 | 3 | | 2016 | 3 | 4 | 7 | | 2017 | 4 | 3 | 7 | | 2018 | 2 | 0 | 2 | | 2019 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Oligopeptides" by people in Profiles.
-
Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P. Oprozomib in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2019 08 16; 9(9):66.
-
Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander KS, Mezzi K, Siegel DS. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019 09; 33(9):2127-2143.
-
Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, Jakubowiak A, Savona MR, Obreja M, Berdeja JG. A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clin Cancer Res. 2019 08 15; 25(16):4907-4916.
-
Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560.
-
Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 08 01; 134(5):421-431.
-
Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J. 2019 01 04; 9(1):3.
-
Gupta A, Xu J, Lee S, Tsai ST, Zhou B, Kurosawa K, Werner MS, Koide A, Ruthenburg AJ, Dou Y, Koide S. Facile target validation in an animal model with intracellularly expressed monobodies. Nat Chem Biol. 2018 09; 14(9):895-900.
-
D'Cruz AA, Kershaw NJ, Hayman TJ, Linossi EM, Chiang JJ, Wang MK, Dagley LF, Kolesnik TB, Zhang JG, Masters SL, Griffin MDW, Gack MU, Murphy JM, Nicola NA, Babon JJ, Nicholson SE. Identification of a second binding site on the TRIM25 B30.2 domain. Biochem J. 2018 01 23; 475(2):429-440.
-
Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 10; 36(8):728-734.
-
Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, Boxer AL. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|